
Opinion|Videos|August 16, 2024
Personalizing Treatment Selection
A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.
Advertisement
Episodes in this series

- How does knowing that type 2 inflammation is a cause influence your treatment selection?
- Beyond identifying the underlying cause, what other patient-specific factors (e.g., age, comorbidities, disease severity) do you consider when selecting treatment regimens for AD or PN?
Advertisement
Related to this article

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.

Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.

Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
4
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
5



